Multiple Myeloma

Disease State Hub

Featured

Timelines
Notable FDA Approvals
Timelines
07/27/2026
July 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...
07/27/2026
FDA Approval
FDA Approval
07/23/2026
Anthony Calabro, MA
The FDA approved subcutaneous isatuximab-irfc (Sarclisa Escena, Sanofi-Aventis US LLC) for multiple myeloma treatment regimens across relapsed, refractory, and newly diagnosed disease settings.
07/23/2026
Timeline Snapshot
physicians looking at ipad
Timeline Snapshot
04/16/2026
March 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...
04/16/2026

Interactive Features

Pop Quiz
Pop Quiz
12/17/2025
Ashton L. Stahl
As researchers continue exploring early-intervention strategies for high-risk smoldering multiple myeloma, understanding the basic pathophysiology of plasma cell disorders (and the targets of emerging...
12/17/2025

Clinical Insights

Multidisciplinary Dialogue, Ep. 8
harrison
Multidisciplinary Dialogue, Ep. 8
09/02/2024
In this episode, Anil Harrison, MD, speaks with Dharminder Singh, MD, about the evaluation of renal tubular acidosis (RTA) and how to evaluate metabolic alkalosis. The first patient case presentation is a...
09/02/2024
expert Q&A
expert Q&A
10/18/2022
Joshua Richter, MD, associate professor of medicine, hematology, and oncology, Tisch Cancer Institute, Icahn School of Medicine, Mount Sinai, reviews real-world data presented at the SOHO 2022 Annual...
10/18/2022